Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

Autor: Schoels, Mm, Van Der Heijde, D, Breedveld, Fc, Burmester, Gr, Dougados, M, Emery, P, Ferraccioli, Gianfranco, Gabay, C, Gibofsky, A, Gomez Reino, Jj, Jones, G, Kvien, Tk, Murakami, M, Murikama, Mm, Nishimoto, N, Smolen, Js
Jazyk: angličtina
Rok vydání: 2013
Předmět:
Settore MED/16 - REUMATOLOGIA
Arthritis
Juvenile
Antirheumatic Agents/therapeutic use
DMARDs (biologic)
Spondylitis
Ankylosing/drug therapy/immunology
Arthritis
Rheumatoid
chemistry.chemical_compound
Rheumatoid
Monoclonal
Immunology and Allergy
skin and connective tissue diseases
Humanized
ddc:616
Arthritis
Juvenile/drug therapy/immunology
Antirheumatic Agents
Systematic review
Antibodies
Monoclonal
Humanized/therapeutic use
Rheumatoid arthritis
Meta-analysis
musculoskeletal diseases
Ankylosing
medicine.medical_specialty
Consensus
Immunology
Rheumatoid Arthritis
Antibodies
Monoclonal
Humanized
General Biochemistry
Genetics and Molecular Biology
Antibodies
Tocilizumab
Rheumatology
Internal medicine
medicine
Humans
Spondylitis
Ankylosing
Juvenile Idiopathic Arthritis
Ankylosing spondylitis
business.industry
Interleukin-6
Clinical and Epidemiological Research
medicine.disease
Arthritis
Juvenile
Arthritis
Rheumatoid/drug therapy/immunology
Interleukin-6/antagonists & inhibitors/immunology
Treatment
chemistry
business
Spondylitis
Zdroj: Annals of the Rheumatic Diseases, 72(4), 583-589
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, Vol. 72, No 4 (2013) pp. 583-9
ISSN: 0003-4967
Popis: Background Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), but also other agents targeting either IL-6 or its receptor are investigated in various indications. Objective To review published evidence on safety and efficacy of IL-6i in inflammatory diseases. Methods We performed systematic literature searches in Medline and Cochrane, screened EULAR and American College of Rheumatology meeting-abstracts, and accessed http://www.clinicaltrials.gov. Results Comprehensive evidence supports the efficacy of tocilizumab in RA in DMARD-naive patients, and after DMARD- and TNFi-failure. Randomised comparisons demonstrate superiority of tocilizumab in JIA, but not ankylosing spondylitis (AS). Other indications are currently investigated. Additional IL-6i show similar efficacy; safety generally appears acceptable. Conclusions IL-6i is effective and safe in RA and JIA, but not in AS. Preliminary results in other indications need substantiation.
Databáze: OpenAIRE
Externí odkaz: